Is the current anti-osteoporotic therapy paradigm good enough?
Fisher
Alexander A
AA
Davis
Michael W
MW
D000368:Aged; D019386:Alendronate / Q000191:economics / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009735:Nursing Homes; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood / Q000502:physiology*; D019379:Teriparatide / Q000191:economics / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019379:Teriparatide; D019386:Alendronate